Muscone Ameliorates Ovariectomy-Induced Bone Loss and Receptor Activator of Nuclear Factor-κb Ligand-Induced Osteoclastogenesis by Suppressing TNF Receptor-Associated Factor 6-Mediated Signaling Pathways
Open Access
- 20 March 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 348
- https://doi.org/10.3389/fphar.2020.00348
Abstract
Postmenopausal osteoporosis is caused by the deficiency of estrogen, which breaks bone homeostasis and induces levels of pro-inflammatory cytokines. Muscone is a potent anti-inflammatory agent and is used to treat bone fracture in traditional Chinese medicine. However, its anti-osteoclastogenic effects remain unclear. For in vitro study, morphology tests of osteoclastogenesis were firstly performed. And then, factors in RANK-induced NF-kappa B and MAPK pathways were examined by RT-PCR and Western blot, and the binding of TNF receptor-associated factor (TRAF)6 to RANK was inspected by coimmunoprecipitation and immunofluorescence staining. For in vivo experiments, C57BL/6 ovariectomized (OVX) mice were used for detection, including H&E staining, TRAP staining, and micro CT. As a result, muscone reduced OVX-induced bone loss in mice and osteoclast differentiation in vitro, by inhibiting TRAF6 binding to RANK, and then suppressed NF-kappa B and MAPK signaling pathways. The expression of the downstream biomarkers was finally inhibited, including NFATc1, CTR, TRAP, cathepsin K, and MMP-9. The inflammatory factors, TNF-a and IL-6, were also reduced by muscone. Taken together, muscone inhibited the binding of TRAF6 to RANK induced by RANKL, thus blocking NF-kB and MAPK pathways, and down-regulating related gene expression. Finally, muscone inhibited osteoclastogenesis and osteoclast function by blocking RANK-TRAF6 binding, as well as downstream signaling pathways in vitro. Muscone also reduced ovariectomy-induced bone loss in vivo.Keywords
This publication has 43 references indexed in Scilit:
- Beneficial effects of muscone on cardiac remodeling in a mouse model of myocardial infarctionInternational Journal of Molecular Medicine, 2014
- TRAF Family Member-Associated NF-κB Activator (TANK) Induced by RANKL Negatively Regulates Osteoclasts Survival and FunctionInternational Journal of Biological Sciences, 2012
- Evidence for osteocyte regulation of bone homeostasis through RANKL expressionNature Medicine, 2011
- Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathwaysJournal of Bone and Mineral Research, 2010
- Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in miceBiochemical Pharmacology, 2010
- Diphenylhydantoin Inhibits Osteoclast Differentiation and Function Through Suppression of NFATc1 SignalingJournal of Bone and Mineral Research, 2009
- Expression of macrophage inhibitory cytokine‐1 in prostate cancer bone metastases induces osteoclast activation and weight lossThe Prostate, 2009
- Effects of Estrogen Replacement Therapies on Mouse Platelet Function and Glycoprotein VI LevelsCirculation Research, 2005
- RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesisThe EMBO Journal, 2005
- Genetic regulation of osteoclast development and functionNature Reviews Genetics, 2003